Human Genome Sciences, Inc., a biopharmaceutical corporation that uses the human DNA sequence to develop protein and antibody drugs, announced in March that George Morrow, M.A. ’77, had been appointed to the HGS Board of Directors.
Until January 2011, Morrow served as executive vice president for global commercial operations for Amgen, Inc., leading all of Amgen’s commercial activities in over 50 countries .
Before joining Amgen, Morrow had over 20 years of commercial experience at Merck and GlaxoWellcome, where he served as president and CEO of GlaxoWellcome Inc. and as managing director of GlaxoWellcome U.K., both subsidiaries of GlaxoSmithKline plc.
Morrow holds a B.S. in chemistry from Southampton College, Long Island University; an M.A. in chemistry from Bryn Mawr College; and an M.B.A. from Duke University’s Fuqua School of Business. He is a member of the Duke University Fuqua School of Business Advisory Board and Medical Center Board of Visitors. He is also a member of the Board of Directors of Align Technology, a global medical device company. He has also previously served on boards for GlaxoWellcome Inc. and Johns Hopkins School of Public Health.